Notoginsenoside R1 is a ginsenoside found in Panax notoginseng that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It is a beta-D-glucoside, a 12beta-hydroxy steroid, a 3beta-hydroxy steroid, a disaccharide derivative, a ginsenoside, a tetracyclic triterpenoid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane.
Notoginsenoside R1 is an active ingredient isolated from Panax notoginseng that induces tissue-type plasminogen activator synthesis in cultured human umbilical vein endothelial cells.
Notoginsenoside R1 has a role as a plant metabolite, an antioxidant, a neuroprotective agent, an apoptosis inducer and a phytoestrogen.
Derived from the dried root of Panax ginseng of the Araliaceae family
Notoginsenoside R1 acts as an anti-inflammatory agent, inhibiting TNF-α induced PAI-1 production in aortic smooth muscle cells in humans.
ChEBI: Notoginsenoside R1 is a ginsenoside found in Panax notoginseng that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It has a role as a plant metabolite, an antioxidant, a neuroprotective agent, an apoptosis inducer and a phytoestrogen. It is a beta-D-glucoside, a 12beta-hydroxy steroid, a 3beta-hydroxy steroid, a disaccharide derivative, a ginsenoside, a tetracyclic triterpenoid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane.
Notoginsenoside R1 has been shown to exhibit antooxidant, anti-inflammatory, antiapoptotic, and immune-stimulatory properties.
Notoginsenoside R1 (5 mg/kg/h; infused via the right jugular vein) increases red blood cell velocity, reduces the number of adherent leukocytes and inhibits mast cell degranulation and cytokine elevation in rats[3].
| Animal Model: | Male Sprague-Dawley (SD) rats (200-250 g)[3] |
| Dosage: | 5 mg/kg/h |
| Administration: | Infused 20 min before LPS infusion via the right jugular vein |
| Result: | Ameliorated the LPS-induced reduction in the mesenteric venular shear rate to some extent.
Attenuated the LPS-induced adhesion of leukocytes to the venular wall.
Inhibited mast cell degranulation and cytokine elevation. |
